Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

  • Do not use Makena in women with any of the following conditions:
    • Current or history of thrombosis or thromboembolic disorders
    • Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
    • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
    • Cholestatic jaundice of pregnancy
    • Liver tumors, benign or malignant, or active liver disease
    • Uncontrolled hypertension
  • Makena should be discontinued if thrombosis or thromboembolism occurs
  • Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of Makena or with other products containing castor oil
  • Women receiving Makena should be monitored if they:
    • Are prediabetic or diabetic
    • Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
    • Have a history of clinical depression; Makena should be discontinued if depression recurs
    • Develop jaundice; consider whether benefit of use warrants continuation
    • Develop hypertension
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
  • In a study where the Makena intramuscular injection was compared with placebo, the most common adverse reactions reported with Makena intramuscular injection (reported incidence in ≥2% of subjects and higher than in the control group) were: injection site reactions (pain [35%], swelling [17%], pruritus [6%], nodule [5%]), urticaria (12%), pruritus (8%), nausea (6%), and diarrhea (2%)
  • In studies where the Makena subcutaneous injection using auto-injector was compared with Makena intramuscular injection, the most common adverse reaction reported with Makena Auto-Injector use (and higher than with Makena intramuscular injection) was injection site pain (10% in one study and 34% in another)

You may report an adverse event related to AMAG Pharmaceuticals' products by calling 1-877-411-2510 or emailing amag@druginfo.com. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.

Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

  • Do not use Makena in women with any of the following conditions:
    • Current or history of thrombosis or thromboembolic disorders
    • Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
    • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
    • Cholestatic jaundice of pregnancy
    • Liver tumors, benign or malignant, or active liver disease
    • Uncontrolled hypertension
  • Makena should be discontinued if thrombosis or thromboembolism occurs
  • Allergic reactions, including urticaria, pruritus and angioedema, have been reported with use of Makena or with other products containing castor oil
  • Women receiving Makena should be monitored if they:
    • Are prediabetic or diabetic
    • Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
    • Have a history of clinical depression; Makena should be discontinued if depression recurs
    • Develop jaundice; consider whether benefit of use warrants continuation
    • Develop hypertension
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
  • In a study where the Makena intramuscular injection was compared with placebo, the most common adverse reactions reported with Makena intramuscular injection (reported incidence in ≥2% of subjects and higher than in the control group) were: injection site reactions (pain [35%], swelling [17%], pruritus [6%], nodule [5%]), urticaria (12%), pruritus (8%), nausea (6%), and diarrhea (2%)
  • In studies where the Makena subcutaneous injection using auto-injector was compared with Makena intramuscular injection, the most common adverse reaction reported with Makena Auto-Injector use (and higher than with Makena intramuscular injection) was injection site pain (10% in one study and 34% in another)

You may report an adverse event related to AMAG Pharmaceuticals' products by calling 1-877-411-2510 or emailing amag@druginfo.com. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.

Show site menu Menu
Hide site menu

Purchasing and Stocking

Makena may be purchased from specialty distributors or direct from a wholesaler and stocked for use as needed

  • Purchase directly from one of the following specialty distributors: Click here for billing resources. Please call the specialty distributor for specific ordering instructions
CuraScript, Inc.
1-877-599-7748
McKesson Plasma and Biologics
1-877-625-2566
TheraCom
1-888-214-8313
CuraScript, Inc.
1-877-599-7748
McKesson Plasma and Biologics
1-877-625-2566
TheraCom
1-888-214-8313
  • Order via drop shipment from your preferred wholesaler: Please contact them directly for more information
download pdfDownload the Makena Billing Guide
Makena Care Connection®

Personalized Patient Support. Healthcare Professional Resources. More Than Makena.

Makena Care Connection® offers personalized support that helps verify insurance and obtain prior authorizations (when applicable), addresses your patients’ financial concerns, and encourages adherence to therapy. Learn More >

Select a topic below to learn more

Billing and coding

Below is billing and coding information that is required for Makena when completing the CMS 1500 claim form. Please note, code and claim information requirements may vary by insurer and benefit plan. Patient coverage and codes should be verified before purchasing and billing.

Code Type Description Code
Code Type: NDC1,*
NDC1,*

Makena® (hydroxyprogesterone caproate injection)

1.1 mL=275 mg per dose

Subcutaneous auto-injector
64011-301-03 OR 64011-0301-03

-OR-

-OR-

Makena® (hydroxyprogesterone caproate injection)

1 mL=250 mg per dose

Single-dose, preservative-free vial
64011-247-02 OR 64011-0247-02

Multi-dose vial (5 weekly injections)
64011-243-01 OR 64011-0243-01

Code Type: Administration procedures: CPT5,†
Administration procedures: CPT5,†

Injection code
(therapeutic, prophylactic, or diagnostic injection)

96372

-OR-

-OR-

Office/outpatient visit codes (new patient; length of visit) (established patient; length of visit)

99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214

Code Type: ICD-10-CM6,‡
ICD-10-CM6,‡ Supervision of pregnancy with history of preterm labor, second trimester O09.212
Supervision of pregnancy with history of preterm labor, third trimester O09.213
Supervision of pregnancy with history of preterm labor, unspecified trimester

O09.219

Note: The ICD-10 codes start with an uppercase “O,” which is followed by a zero.

Code Type: Drug: HCPCS7,8,§
Drug: HCPCS7,8,§ Makena J code J1726 (1 billable unit=10 mg)
Previously J1725 or Q9986

Patient Information and Coding Worksheet

Helps you keep track of your patients’ insurance information and codes needed for reimbursement for Makena.

Download

Makena Billing Guide

Use for assistance when completing the CMS 1500 claim form.

Download

Volume discounts and returns

Volume discount

Offices purchasing Makena may receive a volume discount from their specialty distributor.

Makena returns policy

Under certain circumstances, Makena can be returned for credit. Please see our returns policy to see if your order qualifies.

Makena Returns Policy

Purchasing and stocking FAQs

Have Questions? Connect with us

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

You are now leaving makenahcp.com. AMAG Pharmaceuticals is not responsible for the information contained in any of the linked third-party sites. Please review the site's Privacy Policy and Terms of Use, as AMAG's policies do not apply to third-party sites.

Up arrow
TOP